poisar

Stocks · News reference

BTIG Maintains Buy on Ardelyx, Lowers Price Target to $14

Benzinga Newsdesk

BTIG analyst Julian Harrison maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price target from $17 to $14.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ARDX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Gainey Mckenna & Egleston

    Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. (ARDX)

    A securities class action lawsuit has been filed against Ardelyx, Inc. for allegedly providing misleading statements about its commercial performance while concealing material adverse facts regarding payer access barriers and reimbursement issues for XPHOZAH and IBSRELA. The company reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance on August 6, 2026, causing the stock to decline approximately 18% in a single day.

    ARDX
  2. Benzinga Insights

    Ardelyx Q2 2026 Earnings Call Transcript

    Ardelyx (NASDAQ:ARDX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to

    ARDX